Pomegranate trims blood pressure and cholesterol, but the effects are small

Pomegranate is rich in polyphenols and has long been marketed for heart and metabolic health, but individual trials have been small and their results scattered. Cardiometabolic risk factors, including blood pressure, blood lipids, blood sugar and body weight, are things many readers track and try to improve, so it matters whether a popular supplement moves them at all, and by how much. This review pooled the randomised evidence and looked for dose-response patterns to give a clearer answer than any single trial could offer.

The authors searched PubMed, Scopus and Web of Science for randomised controlled trials of pomegranate supplementation published up to January 2024. After screening, 53 trials with a combined 2306 participants were included. Results were pooled with a random-effects model, disagreement between trials was quantified, and a dose-response meta-analysis probed whether more pomegranate meant bigger effects. Outcomes spanned body weight and BMI, blood pressure, glucose and insulin measures, cholesterol fractions, triglycerides and liver enzymes.

Pomegranate supplementation produced statistically significant but small improvements: lower body weight, BMI, systolic and diastolic blood pressure, fasting blood glucose and total cholesterol, plus higher HDL cholesterol. Just as notable is the list that did not change: waist circumference, waist-to-hip ratio, LDL cholesterol, triglycerides, HbA1c, insulin, insulin resistance and the liver enzymes measured. The overall picture is a gentle nudge across several markers rather than a decisive shift in any one, with long-term blood sugar and the most-watched cholesterol fraction untouched.

This is one of the larger poolings of pomegranate trials to date, and it lands where much of the polyphenol literature does: real but modest effects on blood pressure and a mixed picture on lipids and glucose. It supports earlier suggestions that pomegranate may benefit blood pressure while cooling expectations on LDL and HbA1c. The authors themselves call for randomised trials with longer durations and larger samples, so questions about durability, optimal dose and which populations benefit most remain open.

If you enjoy pomegranate, this is evidence it may gently support blood pressure, HDL and fasting glucose, which reads as a pleasant bonus rather than a treatment. The effect sizes were small, and markers many people watch most closely, including LDL and long-term blood sugar, did not shift. It is a reason to see pomegranate as one minor input alongside the fundamentals, not a shortcut past them.